Updates in the management of Dyslipidaemia in the high and very high risk individual for CV risk reduction
- Author:
Jeyamalar RAJADURAI
1
;
Wan Azman Wan Ahmad
;
Hapizah NAWAWI
;
Choo Gim HOOI
;
Ng Wai KIAT
;
Rosli Mohd ALI
;
Al Fazir OMAR
;
Sazzli KASIM
;
Oteh MASKON
;
David Quek Kwang Leng
Author Information
1. Subang Jaya Medical Centre, Subang Jaya, Selangor
- Publication Type:Original article
- Keywords:
Cardiovascular disease;
hypercholesterolaemia;
statins;
familial hypercholesterolaemia;
statin intolerance;
ezetimibe;
PCSK9-inhibitor
- From:
The Medical Journal of Malaysia
2018;73(3):154-162
- CountryMalaysia
- Language:English
-
Abstract:
mortality and an important cause of morbidity in Malaysiafor several years. To reduce global cardiovascular (CV) riskin the population, primary preventive strategies need to beimplemented. Hypercholesterolaemia is one of the majorrisk factors for CVD. This paper is an expert review on themanagement of hypercholesterolemia focusing on high andvery high risk individuals. In low and Intermediate riskindividuals, therapeutic lifestyle changes (TLC) and ahealthy lifestyle alone may suffice. In high and very high riskindividuals, drug therapy in conjunction with TLC arenecessary to achieve the target LDL-C levels which havebeen shown to slow down progression and sometimes evenresult in regression of atherosclerotic plaques. Statins arefirst-line drugs because they have been shown in numerousrandomized controlled trials to be effective in reducing CVevents and to be safe. In some high risk individuals, despitemaximally tolerated statin therapy, target Low DensityLipoprotein Cholesterol (LDL-C) levels are not achieved.These include those with familial hypercholesterolaemia andstatin intolerance. This paper discusses non-statintherapies, such as ezetimibe and the newer Proproteinconvertase subtilisin/kexin type 9 Inhibitors (PCSK9-i).
